[Hyderabad, April 19th, 2025] – The Anthrax Vaccine Market, valued at USD 1.2 billion in 2023, is expected to grow at a rate of 11.3%, reaching USD 2.8 billion by 2031, driven by military needs and breakthrough adjuvants, reports ClearView Market Insights.
Request Sample @ https://clearviewmarketinsights.com/report-details/global-anthrax-vaccine-market/
2024 Key Advances
- Improved Immunogenicity
- AV7909 achieves 98% seroconversion compared to 83% of legacy vaccines.
- Oral and nasal vaccines enter clinical trials, eliminating the need for needles.
- Logistics Revolution
- Thermostable formulations withstand 25°C for 5 years.
- mRNA platform cuts manufacturing time from 12 months to 4.
- Dual-Use Potential
- TerraCoV2-AM targets both anthrax and coronavirus spikes.
- Livestock applications prevent zoonotic transmission.
Regional Preparedness
- North America (65%): The US maintains a 50 Mn dose stockpile.
- Europe (XX%): NATO countries are standardizing vaccination protocols.
- Asia (XX%): China mandates 100 million livestock doses per year.
Executive Insights
"We're moving from 1950s-era vaccines to 21st century molecular designs."
– Robert Kramer, CEO, Emergent BioSolutions
Roadmap to 2031
- 2025: Next-gen vaccines to comprise 30% of government purchases.
- 2027: Needle-free options approved for civilian use.
- 2030: AI-designed antigens may enter clinical testing.
For more insights, visit https://clearviewmarketinsights.com/report-store
About ClearView Market Insights
ClearView Market Insights track 80+ biodefense markets, from vaccines to detection systems.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
